ruxolitinib

Overview

Ruxolitinib is an oral JAK1/2 inhibitor FDA-approved for myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. In sarcoma it has been explored in functional drug screens where JAK pathway activity may contribute to tumor growth.

Evidence in the corpus

• In the UCLA PDTO sarcoma screen, rapidly progressing tumors (patients with progressive disease at follow-up) showed increased sensitivity to ruxolitinib (p=0.043) compared to non-rapidly-progressing tumors, suggesting that aggressive sarcoma biology may be associated with JAK pathway dependency. PMID:39305899
• Ruxolitinib (JAK1/2 inhibitor) was active against HUT78 CTCL cells harboring a JAK3 p.Ala573Val activating mutation; supports genotype-stratified use in JAK3/STAT3/SH2B3-mutant CTCL PMID:26551667

Resistance mechanisms

• Not reported in corpus.

Cancer types (linked)

• OS, LMS, RMS

Sources

• PMID:39305899 — Duminuco et al. 2024, UCLA PDTO sarcoma functional screen; association with rapidly progressive disease phenotype.

This page was processed by crosslinker on 2026-05-14. - PMID:26551667

This page was processed by crosslinker on 2026-05-14.